Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Dec 24, 2020; 11(12): 1076-1083
Published online Dec 24, 2020. doi: 10.5306/wjco.v11.i12.1076
Published online Dec 24, 2020. doi: 10.5306/wjco.v11.i12.1076
Endometrial clear cell carcinoma invading the right oviduct with a cooccurring ipsilateral oviduct adenomatoid tumor: A case report
Zhi-Xiong Hu, Min-Hua Tan, Wei Chen, Zhi-Hao Xie, Yong-Jian Zhou, Qing Liang, Department of Pathology, The First People’s Hospital of Zhaoqing, Zhaoqing 526020, Guangdong Province, China
Qiong-Zhen Li, Department of Gynaecology and Obstetrics, The First People’s Hospital of Zhaoqing, Zhaoqing 526020, Guangdong Province, China
Jia-Li Xu, Department of Radiology, The First People’s Hospital of Zhaoqing, Zhaoqing 526020, Guangdong Province, China
Jian-Hong An, School of Medicine, South China University of Technology, Guangzhou 510006, Guangdong Province, China
Hong Shen, Department of Pathology, Southern Medical University, Guangzhou 510515, Guangdong Province, China
Author contributions: Hu ZX contributed to pathological diagnosis, collecting the patient's medical records and pathological pictures, and writing the first draft of the paper; Tan MH contributed to pathological diagnosis and data management; Li QZ performed the surgery; Xu JL performed B-ultrasound examination; Chen W contributed to gross specimen picture arrangement; Xie ZH contributed to taking the pathological biopsy and taking photos; Zhou YJ contributed to H&E staining; Liang Q contributed to immunohistochemical staining; An JH contributed to translation and submission of the paper; Shen H contributed to study design, data analysis, conclusion extraction, and guiding paper writing, modification, and finalization.
Informed consent statement: The patient provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors declare that they have no competing interests.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hong Shen, PhD, Chief Doctor, Department of Pathology, Southern Medical University, Shatai South Road, Baiyun District, Guangzhou 510515, Guangdong Province, China. shenhong2010168@163.com
Received: August 21, 2020
Peer-review started: August 21, 2020
First decision: September 13, 2020
Revised: September 27, 2020
Accepted: October 15, 2020
Article in press: October 15, 2020
Published online: December 24, 2020
Processing time: 119 Days and 6.8 Hours
Peer-review started: August 21, 2020
First decision: September 13, 2020
Revised: September 27, 2020
Accepted: October 15, 2020
Article in press: October 15, 2020
Published online: December 24, 2020
Processing time: 119 Days and 6.8 Hours
Core Tip
Core Tip: In pathological diagnosis, when investigating invasion of the oviduct, one should pay close attention to distinguishing whether the endometrial clear cell carcinoma invades the oviduct or whether it is accompanied by an oviduct adenomatoid tumor. The significance of this investigation is to determine whether the endometrial adenocarcinoma has tubal metastasis. This is critical for the confirmation of T3a in tumor-node-metastasis staging.